Most symptoms during GLP-1 treatment are mild to moderate, begin at initiation or after a dose increase, and ease with time. Vomiting in particular usually resolves within one to eight days.

What marks a symptom out is not the sensation itself but its severity, how long it persists, and whether it arrives with systemic signs: fainting, confusion, fever, jaundice, very little urine, or an inability to keep fluid down. Six presentations need urgent assessment, and four of those need care the same hour rather than the next available appointment.

Key Takeaways:

• Ordinary nausea from GLP-1 treatment is unpleasant and intermittent. Nausea that is severe, prevents drinking, or arrives with abdominal pain is a different event.
• Vomiting that is brief and allows fluid intake is expected. Vomiting with faintness, very little urine or confusion needs same-day urgent care.
• Acute abdominal or back pain that is severe and persistent is not a gastrointestinal side effect. It needs same-hour assessment for pancreatitis.
• A sudden painless change in vision in one eye needs same-day emergency assessment. It is not the same as transient blur caused by glucose shifts.
• Low blood glucose severe enough to cause fainting or confusion needs care the same hour. A useful marker for severity: whether you can drink a glass of water and keep it down.

Urgency runs top to bottom. Nothing below is a diagnosis, and none of it replaces an examination. It is a guide to how quickly to get one.

Read each possibility in the second column as something a clinician will test, not a conclusion you can reach at home. Several of these presentations share their early features with the ordinary effects of treatment, which is why the next section deals with that distinction directly.

Act this hour, call 112 or go to emergency:

• Severe, persistent pain in the upper abdomen, especially going through to the back, with or without vomiting: May indicate acute pancreatitis rather than ordinary transient nausea. Product labelling directs that treatment is stopped where pancreatitis is suspected, and not restarted if it is confirmed.
• Severe constipation with swelling or distension, cramping or vomiting, and no stool or gas passing at all: May indicate bowel obstruction or ileus rather than uncomplicated constipation. Go to emergency now.
• Sudden painless loss of vision, dimming, or a new blind area in one eye: May indicate an eye or vascular emergency, including ischaemic optic neuropathy. Emergency eye assessment now, not a routine appointment. The urgency holds regardless of whether the medicine had anything to do with it.
• Sweating, shaking, hunger, palpitations, dizziness or confusion in someone also taking insulin or a sulfonylurea: May indicate hypoglycaemia, which these combinations make more likely. Act immediately on the hypoglycaemia plan the prescriber has given you. Call emergency services for seizure, unconsciousness, inability to swallow, or recovery that keeps recurring.

Act the same day, seek assessment today, not next week:

• Repeated or persistent vomiting together with very little urine, dizziness on standing, faintness, marked weakness or confusion: May indicate volume depletion, electrolyte disturbance or acute kidney injury. Same-day urgent assessment. Emergency care if fainting, confusion or inability to keep fluid down appears.
• Steady pain in the upper right or upper middle abdomen after food, especially fatty food, lasting beyond four to six hours, or with fever or jaundice: May indicate biliary colic, gallbladder inflammation or a blocked duct. Same-day urgent assessment. Emergency care if the pain is severe, or there is fever, jaundice or confusion.

The two same-day rows also escalate: a wait that is reasonable at nine in the evening stops being reasonable the moment fainting, confusion or an inability to drink appears.

The distinction that matters is rarely the symptom's name. It is the character of it, and it is where most people hesitate at two in the morning.

Abdominal discomfort during the first weeks of treatment is typically vague, diffuse and intermittent. Pancreatic pain is different: severe, persistent, concentrated in the upper abdomen, often boring through to the back, and it does not settle between episodes. Gallbladder pain has its own signature, arriving steadily after a meal and outlasting the four-to-six-hour mark rather than fading as digestion finishes.

Vomiting follows the same logic. Vomiting that is unpleasant but brief, with normal urine output and no dizziness on standing, is following the pattern the trial data describe. Vomiting that repeats, stops fluid going down, and brings faintness, weakness or confusion with it is a different event, because the problem has become dehydration rather than nausea.

Constipation divides the same way. In the uncomplicated version, gas is still passing and the abdomen is not progressively swelling. It is the absence of both stool and gas, alongside distension, that turns it into an emergency.

Low blood glucose is the one row that depends on the rest of the prescription rather than the symptom alone. On a GLP-1 medicine alone the risk is low, and the same shakiness usually means something else. Alongside insulin or a sulfonylurea it needs immediate action. A useful marker is whether you can drink a glass of water and keep it down.

What a normal reading looks like is worth knowing before an episode rather than during one. Day-to-day nausea, reflux and constipation that stay in the expected range are a separate problem.

Knowing roughly what happens on arrival makes the decision to go easier, and it also makes clear why none of these can be settled at home.

• For suspected pancreatitis: A clinician examines the abdomen and checks lipase or amylase. Diagnosis requires two of three things under the ACG guideline: characteristic pain, enzymes more than three times the upper limit of normal, or characteristic imaging. Ultrasound is used to look for gallstones, and CT is reserved for uncertainty or failure to improve.
• For suspected gallbladder disease: Examination, liver tests, a blood count and inflammation markers, and an ultrasound. Product information for these medicines specifically calls for gallbladder studies where the condition is suspected.
• For dehydration or kidney injury: Pulse and blood pressure including the change on standing, urine output, glucose, electrolytes, urea and creatinine. An ECG is added where there is severe weakness, palpitations or a suspicion of major electrolyte disturbance.
• For suspected obstruction: Examination, blood count, electrolytes and renal function, and abdominal imaging, usually CT.
• For a hypoglycaemic episode: Confirmed with a bedside glucose reading, after which the useful work is the medication and meal history and why it recurred. Indian diabetes recommendations treat that review as part of managing the episode rather than an optional follow-up.

For an eye emergency: Assessment starts with visual acuity, pupils and the fundus, with further tests decided by what those show.

No national India-specific triage pathway for GLP-1 adverse events was located. The route is the ordinary emergency one: the nearest emergency department capable of imaging and blood tests. India's unified emergency number is 112, which dispatches health services through state systems.

Where the presentation is one of the emergency rows, the call to make is to emergency services or a hospital rather than to a clinic appointment line, because the assessments above need imaging and laboratory tests that a consulting room does not carry.

Two things are worth taking, or telling someone to bring:

• The product pack or prescription, because the assessing clinician will not otherwise know which medicine is involved.
• The full list of everything else being taken, insulin and sulfonylureas above all, since that single fact changes how a low-glucose episode is interpreted.

The decision to withhold, stop or restart the medicine afterwards belongs to the prescriber. That is part of the wider case for clinical supervision, and it is not a decision to make on the way to hospital or in the days after.

The honest summary is that severity, persistence and systemic signs are the signal. The sensation alone is not.

Anything that falls short of those descriptions is still worth raising at the next contact rather than absorbed quietly, because a pattern over weeks is often what a prescriber needs to see. If you are unsure which side of the line a symptom sits on, treat that uncertainty as the reason to speak to a registered medical practitioner rather than a reason to wait. Bring the timing and the exact character of the symptom, along with when the last dose was taken and what else you are prescribed.

Any of these symptoms and not sure whether it needs same-day attention? Speak to a Voy clinician, do not wait for your next scheduled review.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.